Teva's Pivot to Growth stopped being a slogan in the June quarter, when three neuroscience brands replaced an entire year of fading generic Revlimid economics in a single print. The Israeli manufacturer is becoming a central-nervous-system specialty company, and that mix shift is now large enough to hold the top line nearly flat even as the old volume engine shrinks. The debate is no longer whether the brands can grow. It is whether they can carry a still-levered balance sheet through a Medicare price reset and a late-year destock without giving the multiple back.
Combined Austedo, Ajovy, and Uzedy sales cleared $1 billion in the quarter. Local-currency growth exceeded forty percent. That growth more than offset the United States generics hole left by lenalidomide. Headline revenue still slipped 1% because the rest of the generics book is not growing. Cash conversion stayed intact. Free cash flow rose even as reported earnings swung to a loss on the Emalex in-process research charge. The market is already treating that charge as noise.
The next twelve months resolve three things. Whether Austedo demand survives the Medicare maximum-fair-price reset and a planned fourth-quarter destock. Whether Uzedy plus the pending olanzapine long-acting injection can turn a schizophrenia franchise into a second growth engine. And whether net leverage keeps falling toward the two-times target while legal runoff and a swollen short-term debt stack still sit on the balance sheet. Shares closed near $39, roughly double the fifty-two-week low, so a large part of the turnaround is already in the price.